<!DOCTYPE html>
<html>
<head>
  <meta charset="utf-8">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black-translucent">

  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0;"/>
  <!-- disable numbers becoming dialable -->
  <meta name="format-detection" content="telephone=no" />

  <link rel="stylesheet" href="content/css/slideshow.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/thumbnailmenu.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/topmenu.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/referencepopup.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/typography.css" type="text/css" charset="utf-8">
   	  
  <link rel="stylesheet" href="content/css/home.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/current_treatment.css" type="text/css" charset="utf-8">
 
  <link rel="stylesheet" href="content/css/references.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/efficacy.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/efficacy0.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/efficacy1.css" type="text/css" charset="utf-8">
   
  <link rel="stylesheet" href="content/css/rocket_af.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/rocket_af0.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/rocket_af1.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/rocket_af2.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/stroke_in_af.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/xeralto.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/safety.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/safety0.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/administration.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/summary.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/cover.css" type="text/css" charset="utf-8">
  <link rel="stylesheet" href="content/css/moa.css" type="text/css" charset="utf-8">
  
 <script type="text/javascript" src="viewer/js/monitor.js"></script>
 <script src="../viewer/js/pdf.js"></script>
  
  <script type="text/javascript" src="ALF/lib/zepto.js"></script>
  <script type="text/javascript" src="ALF/lib/iscroll.js"></script>
  <script type="text/javascript" src="ALF/controller/slidescontroller.js"></script>
  <script src="ALF/lib/slidescroller.js" type="text/javascript" charset="utf-8"></script>
  <script type="text/javascript" src="ALF/utils/dispatchEvent.js"></script>
  <script type="text/javascript" src="ALF/lib/touchy.js"></script>
 
  <script type="text/javascript" src="ALF/model/model.js"></script>
  <script type="text/javascript" src="ALF/view/slides.js"></script> 

  <script type="text/javascript" src="ALF/view/navigation.js"></script>
  <script type="text/javascript" src="ALF/controller/navigationcontroller.js"></script>
  <script type="text/javascript" src="ALF/controller/thumbcontroller.js"></script>
  <script type="text/javascript" src="ALF/controller/slidescontroller.js"></script>
  <script type="text/javascript" src="ALF/controller/footercontroller.js"></script>
  
  <script type="text/javascript" src="ALF/view/thumbnavigation.js"></script>
  <script type="text/javascript" src="ALF/view/footer.js"></script>
  <script type="text/javascript" src="ALF/view/footer.js"></script>
 
 
  <script type="text/javascript" src="ALF/utils/include.js"></script>
  <script type="text/javascript" src="ALF/utils/gesture.js"></script>
  <script type="text/javascript" src="ALF/appinit.js"></script>
  
  <script type="text/javascript">	 
		 
	 var model = new Model();
	 var slideShow = new SlideShow();
	 var app = new App();
	 
	 function init() {
	 		  
		model.dynamic = false;
		app.init();
		slideShow.init = true;
		//monitoringEnabled = true;
	    //gestures.addSwipeListener('swipebutton');
	    document.addEventListener('swipeleft', function() {console.log('I heard a swipeleft'); model.swipe = true});
	   } 
	   document.ontouchmove = function(e){
	     e.preventDefault();
	   };    	   
  	   window.addEventListener('load',init, false);
	</script>
  

<title>Bayer Xarelto</title>
  
</head>
<body>
<div id="container" class="container">
<div id="topnavwrapper">

   <nav id="topnav" class="topnav">
	  <ul id="nav">
	  	<li>References</li>
	  	<li id="homebutton" class="home"></li>
	  	<li>Stroke in AF</li>
	  	<li>Current Treatment</li>
	  	<li>Xarelto<sup>&reg;</sup></li>
	  	<li>Rocket AF</li>
	  	<li>Efficacy</li>
	  	<li>Safety</li>
	  	<li>Administration</li>
	  	<li>Summary</li>
	  </ul>   
   </nav>
 
  </div> 
  
   <div id="wrapper">
   <!--<div id="test">test</div>-->
   <div id="scroller">
   
   <section id="references_section" class="slide">
	<article id="references1" data-monitorId="References">
	<div id="referencecontent" class="slide1">
		<h1>SPAF References library</h1>
		  <div class="wrapper">
			  <ul class="references scroller">
			    <li>
				<a href="javascript:openPDF('docs/Ref01_Di_Carlo-Humanandeconomicburdenofstroke.pdf');"><span>1.</span>
					Di Carlo A. Human and economic burden of stroke. Age Ageing. 2009;38(1):4-5. </a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref02_Kannel-PrevalenceincidencePrognosis.pdf');"><span>2.</span>
				  Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation:
				  population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N. </a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref03_Marinietal-ContributionofAtrialFibrillationtoIncidenceandOutcomeofIschemicStroke.pdf');"><span>3.</span>
				  Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke.
				  2005;36(6):1115-1119.</a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref04_Gladstone-PotentiallyPreventableStrokesinHigh-RiskPatientsWithAtrialFibrillation.pdf');"><span>4.</span>
				   Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235-240. </a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref05_Warfarin_SPC.pdf');"><span>5.</span>
					Warfarin [summary of product
					characteristics]. Frimley, Camberley, Surrey, United Kingdom: Sandoz Ltd; October 2010. </a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref06_Waldo-HospitalizedPatientsWithAtrialFibrillationandaHighRiskofStroke.pdf');"><span>6.</span>
				 Waldo AL, Becker RC, Tapson VF, et al; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729-1736.
				 </a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
				   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref08_Perzborn-Thediscoveryanddevelopmentofrivaroxaban.pdf');"><span>8.</span>
		         Perzborn E, Roehrig S, Straub A, et al. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2010;10(1):61-75.
				</a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref09_Perzborn-Invitroandinvivostudiesofthenovelantithromboticagent.pdf');"><span>9.</span>
				 Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic
				   agent BAY 59-7939—an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514-521. </a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref10_Weitz-Newanticoagulants.pdf');"><span>10.</span>
				   Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3(8):1843-1853.</a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref11_DesignRocketAF.pdf');"><span>11.</span>
				  The Executive Steering Committee, on
				  behalf of the ROCKET AF Study Investigators. Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of
				  the ROCKET AF study. Am Heart J. 2010;159(3):340-347. </a>
				</li>
				<li class="none">
				 <span>12.</span>
				  Data on file. Bayer HealthCare AG, Berlin, Germany.
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref13_Hacke-BaselinecharacteristicsofROCKETAFstudy.pdf');"><span>13.</span>
				  Hacke W, Patel MR, Becker RC, et al. Baseline characteristics of the ROCKET AF study: comparison with recent
				  atrial fibrillation studies. Abstract OAID 5 presented at the 19th European Stroke Conference (ESC); May 25-28, 2010: Barcelona, Spain 2010.
				  </a>
				</li>
				<li>
				<a href="javascript:openPDF('docs/Ref14_EuropeanHeartRhythmAssociation.pdf');"><span>14.</span>
				 European Heart Rhythm Association; Heart Rhythm Society, Fuster V, et al. ACC/AHA/
				 ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of
				 Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854-906. 
				  </a>
				</li>
				<li>
				 <a href="javascript:openPDF('docs/Ref15_Kubitza-Safetypharmacodynamics.pdf');"><span>15.</span>
				  Kubitza D, Becka M, Wensing G,
				  et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880.</a>
				</li>
			</ul>
		</div>
		</div>
		
	 </article>
	 </section>
	  
	  <section id="home_section" class="slide">  
	  	 <article id="home1" data-monitorId="Treatment of Venous Thromboembolism">
	  	   <div class="slide0" id="home">
	  	   <div class="frontLeg"><p class="legTitle">Treatment of<br />Venous Thromboembolism</p></div>
	  	   <div class="frontSpafContainer">
	  	   <div class="frontBrain"><img src="content/images/home/shadowDividingline.png" /></div>
	  	   <p class="frontTitle">Stroke Prevention<br />for Patients with Atrial Fibrillation</p>
	  	   <div class="frontVein"><br /></div>
	  	   </div>
	  	   </div>
	  	</article>
	   </section>
	   	   
	   <section id="stroke_in_af_section" class="slide">
	   			<article id="stroke_in_af" data-monitorId="Stroke Disables and Kills Millions Worldwide">
	   			   <div class="slide3" id="stroke_stickmen">
	   				  <h1>
	   			   <span>Stroke Disables and Kills<br/>
	   			   Millions Worldwide<sup>1</sup></span>
	   		   </h1>
	   	
	   		   <p class="subHead">
	   		   <em>
	   			   Patients with atrial fibrillation (AF) have an<br/>
	   			   increased risk of stroke compared with the general population<sup>2</sup>:
	   		   </em>
	   		   </p>
	   		   <ul class="foldContainer">
	   			   <li class="foldButton0">None</li>
	   			   <li class="foldButton2">2-FOLD</li>
	   			   <li class="foldButton3">3-FOLD</li>
	   			   <li class="foldButton4">4-FOLD</li>
	   			   <li class="foldButton5">5-FOLD</li>
	   		   </ul>
	   			<div class="module">
	   			   <p class="slide3Statement0"><em>AF strokes more severely impact patients compared<br />with other strokes<sup>2</sup></em></p>
	   			   <ul>
	   				   <li class="slide3Statement1">In the year following a stroke, AF patients face a<br /><b>50%</b> risk of death<sup>3</sup></li>
	   				   <li class="slide3Statement2">More than <b>half</b> of patients with AF-related<br />strokes will become disabled<sup>4</sup></li>
	   			   </ul>
	   			</div>
	   		   <div class="stickMan stickMan0 fold4 fold3 fold2 fold0"></div>
	   		   <div class="stickMan stickMan1 fold4 fold3 fold2 fold0"></div>
	   		   <div class="stickMan stickMan2 fold4 fold3 fold2"></div>
	   		   <div class="stickMan stickMan3 fold4 fold3 fold2"></div>
	   		   <div class="stickMan stickMan4 fold4 fold3"></div>
	   		   <div class="stickMan stickMan5 fold4 fold3"></div>
	   		   <div class="stickMan stickMan6 fold4"></div>
	   		   <div class="stickMan stickMan7 fold4"></div>
	   		   <div class="stickMan stickMan8"></div>
	   		   <div class="stickMan stickMan9"></div>
	   		</div>
	   		</article>
	   	   </section>
	   		
	   	<section id="current_treatment_section" class="slide">
	   		<article id="current_treatment" monitor-id="" data-monitorId="Warfarin Limitations can Leave Many Patients Unprotected">
	   			<div class="slide4 content-wrapper">
	   				<h1>Warfarin Limitations can Leave Many Patients Unprotected</h1>
	   				<p>Anticoagulation effectively prevents strokes, yet<br />
	   				<em>Warfarin drawbacks can challenge even your best efforts<sup>5</sup></em></p>
	   				<div class="card-container">
	   					<div class="card">
	   						<ul class="boxes module face front">
	   							<li><span>Unpredictable<br />anticoagulation</span></li>
	   							<li><span>Frequent dose<br />adjustments</span></li>
	   							<li><span>Coagulation monitoring</span></li>
	   							<li><span>Many drug-drug<br />interactions</span></li>
	   							<li><span>Dietary restrictions</span></li>
	   							<li><span>Patient adherence</span></li>
	   						</ul>
	   						<ul class="men module face back">
	   							<li><br /></li>
	   							<li><br /></li>
	   							<li><br /></li>
	   							<li><br /></li>
	   							<li><br /></li>
	   							<li><br /></li>
	   							<li><br /></li>
	   							<li><br /></li>
	   							<li><br /></li>
	   							<li><br /></li>
	   						</ul>
	   					</div>
	   				</div>
	   				<p class="subTextMain hideElem"><em>The potential result of limitations-AF patients receive<br /> no anticoagulation or inadequate anticoagulation</em></p>
	   				<ul class="subTexts">
	   					<li class="hideElem subText1">Despite guidelines, only <span class="pinkEm">50%</span> of AF patients<br />who need prophylaxies recieve it<sup>6</sup></li>
	   					<li class="hideElem subText2">Only <span class="pinkEm">1 in 10</span> AF patients is adequately<br />anticoagulated at the time of first stroke<sup>4</sup></li>
	   				</ul>
	   			</div>
	   		 </article>
	   	   </section>
	   	   
	   	<section id="xarelto_section" class="slide">
	      <article class="innerslide morebelow" id="xarelto_slide1">
	   			<div class="slide5">
	   				 <h1><span>One-Tablet, Once-Daily Xarelto<sup>®</sup><br />Simplifies Protection from Stroke<sup>7</sup></span></h1>
	   				 <div class="module clean">
	   					   <p>SHIFT TO SIMPLE PROTECTION</p>
	   				   </div>
	   
	   					<div id="pilldrag" class="dragdealer">
	   						<div class="handle"></div>
	   					</div>
	   
	   					<table>
	   						<tr>
	   						   <td class="noborder"><br /></td>
	   						   <td class="warfarin noborder" rowspan="2">warfarin<br /><span>VKAs</span><sup>5</sup></td>
	   						   <td class="xarelto noborder" rowspan="2">Xarelto<br /><span>Direct Factor Xa<br />Inhibitor</span><sup>8</sup>
	   						   </td>
	   					   </tr>
	   						<tr>
	   						   <td class="noborder"><br /></td>
	   					   </tr>
	   						<tr>
	   						   <td>Once-daily administration</td>
	   						   <td class="warfarin stateChecked"></td>
	   						   <td class="xarelto stateChecked"></td>
	   					   </tr>
	   						<tr>
	   						   <td>Fast onset of action</td>
	   						   <td class="warfarin">&nbsp;</td>
	   						   <td class="xarelto stateChecked"></td>
	   					   </tr>
	   						<tr>
	   						   <td>Reliable fixed dose</td>
	   						   <td class="warfarin">&nbsp;</td>
	   						   <td class="xarelto stateChecked"></td>
	   					   </tr>
	   						<tr>
	   						   <td>No need for coagulation monitoring</td>
	   						   <td class="warfarin"></td>
	   						   <td class="xarelto stateChecked"></td>
	   					   </tr>
	   						<tr>
	   						   <td>Low risk of drug-drug interactions</td>
	   						   <td class="warfarin"></td>
	   						   <td class="xarelto stateChecked"></td>
	   					   </tr>
	   						<tr>
	   						   <td>No dietary restrictions</td>
	   						   <td class="warfarin"></td>
	   						   <td class="xarelto stateChecked"></td>
	   					   </tr>
	   						<tr>
	   						   <td colspan="3" class="endStatement"><p>The end of complicated anticoagulation.<br />The beginning of simple stroke prevention.</p></td>
	   					   </tr>
	   					</table>
	   			   </div>
	   		 </article>
	   		
	   		 <article class="innerslide moreabove moa moa-xarelto" id="xarelto_slide2">
					<div class="content-wrapper">

						<h1>The Science Behind Simple and<br />Effective Stroke Prevention</h1>
						<p><em>Xarelto<sup>&reg;</sup> precisely targets the pivotal point in the<br />coagulation cascade to prevent thrombin burst<sup>5</sup></em></p>

						<div class="moa-nav">
							<div class="moa-nav-inner">
								<ul>
									<li class="moa-xarelto">Xarelto</li>
									<li class="moa-ufh" >UFH</li>
									<li class="moa-vitamin" >Vitamin K</li>
									<li class="moa-lmwh" >LMWH</li>
									<li class="moa-fondaparinux" >Fondaparinux</li>
									<li class="moa-dti" >DTI</li>
								</ul>
							</div>
						</div>

						<ul class="moa-legend">
							<li class="active">active factor</li>
							<li class="inactive">inactive factor</li>
							<li class="catalysis">catalysis</li>
							<li class="transformation">transformation</li>
						</ul>

						<div class="moa-ani moa-xarelto-ani">
							<div class="moa-initiation">INITIATION</div>
							<div class="moa-propagation">PROPAGATION</div>
							<div class="moa-clotformation">CLOT FORMATION</div>

							<div class="moa-part moa-xarelto-x">X</div>
							<div class="moa-part moa-xarelto-tf">TF</div>
							<div class="moa-part moa-xarelto-viia">VIIa</div>
							<div class="moa-part moa-xarelto-ix">IX</div>
							<div class="moa-part moa-xarelto-ixa">IXa</div>
							<div class="moa-part moa-xarelto-xa">Xa</div>
							<div class="moa-part moa-xarelto-ii">II</div>
							<div class="moa-part moa-xarelto-iia">IIa</div>

							<div class="moa-text moa-xarelto-prothrombin">Prothrombin</div>
							<div class="moa-text moa-xarelto-thrombin">Thrombin</div>
							<div class="moa-text moa-xarelto-fibrinogen">Fibrinogen</div>
							<div class="moa-text moa-xarelto-fibrin">Fibrin</div>

							<div class="moa-line-solid moa-xarelto-x-xa">X -> Xa</div>
							<div class="moa-line-dashed moa-xarelto-tf-xa">TF -> Xa</div>
							<div class="moa-line-dashed moa-xarelto-tf-ixa">TF -> IXa</div>
							<div class="moa-line-solid moa-xarelto-ix-ixa">IX -> IXa</div>
							<div class="moa-line-dashed moa-xarelto-ixa-xa">IXa -> Xa</div>
							<div class="moa-line-dashed moa-xarelto-xa-iia">Xa -> IIa</div>
							<div class="moa-line-solid moa-xarelto-ii-iia">II -> IIa</div>
							<div class="moa-line-dashed moa-xarelto-iia-fibrin">IIa -> fibrin</div>
							<div class="moa-line-solid moa-xarelto-fibrinogen-fibrin">Fibrinogen -> fibrin</div>

							<div class="moa-xarelto-brand">Xarelto&reg;</div>
							<div class="moa-xarelto-info">Direct inhibition of both free Factor Xa and Factor Xa bound in the prothrombinase complex</div>
							<div class="moa-xarelto-arc">Xarelto -> Ax</div>

							<div class="moa-xarelto-glow moa-xarelto-glow-a"></div>
							<div class="moa-xarelto-glow moa-xarelto-glow-b"></div>
							<div class="moa-xarelto-glow moa-xarelto-glow-c"></div>
						</div>

						<div class="moa-ani moa-ufh-ani">
							<div class="moa-initiation">INITIATION</div>
							<div class="moa-propagation">PROPAGATION</div>
							<div class="moa-clotformation">CLOT FORMATION</div>

							<div class="moa-part moa-ufh-x">X</div>
							<div class="moa-part moa-ufh-tf">TF</div>
							<div class="moa-part moa-ufh-viia">VIIa</div>
							<div class="moa-part moa-ufh-ix">IX</div>
							<div class="moa-part moa-ufh-ixa">IXa</div>
							<div class="moa-part moa-ufh-xa">Xa</div>
							<div class="moa-part moa-ufh-ii">II</div>
							<div class="moa-part moa-ufh-iia">IIa</div>

							<div class="moa-part moa-ufh-ii-a">II</div>
							<div class="moa-part moa-ufh-ii-b">II</div>
							<div class="moa-part moa-ufh-ii-c">II</div>
							<div class="moa-part moa-ufh-ii-d">II</div>

							<div class="moa-part moa-ufh-iia-a">IIa</div>
							<div class="moa-part moa-ufh-iia-b">IIa</div>
							<div class="moa-part moa-ufh-iia-c">IIa</div>
							<div class="moa-part moa-ufh-iia-d">IIa</div>

							<div class="moa-text moa-ufh-prothrombin">Prothrombin</div>
							<div class="moa-text moa-ufh-thrombin">Thrombin</div>
							<div class="moa-text moa-ufh-fibrinogen">Fibrinogen</div>
							<div class="moa-text moa-ufh-fibrin">Fibrin</div>

							<div class="moa-line-solid moa-ufh-x-xa">X -> Xa</div>
							<div class="moa-line-dashed moa-ufh-tf-xa">TF -> Xa</div>
							<div class="moa-line-dashed moa-ufh-tf-ixa">TF -> IXa</div>
							<div class="moa-line-solid moa-ufh-ix-ixa">IX -> IXa</div>
							<div class="moa-line-dashed moa-ufh-ixa-xa">IXa -> Xa</div>
							<div class="moa-line-dashed moa-ufh-xa-iia">Xa -> IIa</div>
							<div class="moa-line-solid moa-ufh-ii-iia">II -> IIa</div>
							<div class="moa-line-dashed moa-ufh-iia-fibrin">IIa -> fibrin</div>
							<div class="moa-line-solid moa-ufh-fibrinogen-fibrin">Fibrinogen -> fibrin</div>

							<div class="moa-ufh-brand">UFH</div>
							<div class="moa-ufh-info-a">Factor Xa bound in the prethrombinase complex remains active</div>
							<div class="moa-ufh-info-b">Indirect inhibition of free Factor Xa</div>
							<div class="moa-ufh-info-c">Inhibition of Factor IIa</div>

							<div class="moa-ufh-arc-a">UFH -> Ax</div>
							<div class="moa-ufh-arc-b">UFH -> IIa</div>

							<div class="moa-ufh-glow moa-ufh-glow-a"></div>
							<div class="moa-ufh-glow moa-ufh-glow-b"></div>
							<div class="moa-ufh-glow moa-ufh-glow-c"></div>
						</div>

						<div class="moa-ani moa-vitamin-ani">
							<div class="moa-initiation">INITIATION</div>
							<div class="moa-propagation">PROPAGATION</div>
							<div class="moa-clotformation">CLOT FORMATION</div>

							<div class="moa-part moa-vitamin-x">X<span>VKA</span></div>
							<div class="moa-part moa-vitamin-tf">TF</div>
							<div class="moa-part moa-vitamin-viia">VIIa</div>
							<div class="moa-part moa-vitamin-ix">IX<span>VKA</span></div>
							<div class="moa-part moa-vitamin-ixa">IXa</div>
							<div class="moa-part moa-vitamin-xa">Xa</div>
							<div class="moa-part moa-vitamin-ii">II<span>VKA</span></div>
							<div class="moa-part moa-vitamin-iia">IIa</div>

							<div class="moa-part moa-vitamin-vii">VII<span>VKA</span></div>

							<div class="moa-text moa-vitamin-prothrombin">Prothrombin</div>
							<div class="moa-text moa-vitamin-thrombin">Thrombin</div>
							<div class="moa-text moa-vitamin-fibrinogen">Fibrinogen</div>
							<div class="moa-text moa-vitamin-fibrin">Fibrin</div>

							<div class="moa-line-solid moa-vitamin-x-xa">X -> Xa</div>
							<div class="moa-line-dashed moa-vitamin-tf-xa">TF -> Xa</div>
							<div class="moa-line-dashed moa-vitamin-tf-ixa">TF -> IXa</div>
							<div class="moa-line-solid moa-vitamin-ix-ixa">IX -> IXa</div>
							<div class="moa-line-dashed moa-vitamin-ixa-xa">IXa -> Xa</div>
							<div class="moa-line-dashed moa-vitamin-xa-iia">Xa -> IIa</div>
							<div class="moa-line-solid moa-vitamin-ii-iia">II -> IIa</div>
							<div class="moa-line-dashed moa-vitamin-iia-fibrin">IIa -> fibrin</div>
							<div class="moa-line-solid moa-vitamin-fibrinogen-fibrin">Fibrinogen -> fibrin</div>

							<div class="moa-line-solid moa-vitamin-vii-viia">VII -> VIIa</div>

							<div class="moa-vitamin-info">Vitamin K Antagonists (VKAs) inhibit the synthesis of the coagulation Factors II, VII, IX & X</div>

							<div class="moa-vitamin-glow moa-vitamin-glow-a"></div>
							<div class="moa-vitamin-glow moa-vitamin-glow-b"></div>
							<div class="moa-vitamin-glow moa-vitamin-glow-c"></div>
							<div class="moa-vitamin-glow moa-vitamin-glow-d"></div>
						</div>

						<div class="moa-ani moa-lmwh-ani">
							<div class="moa-initiation">INITIATION</div>
							<div class="moa-propagation">PROPAGATION</div>
							<div class="moa-clotformation">CLOT FORMATION</div>

							<div class="moa-part moa-lmwh-x">X</div>
							<div class="moa-part moa-lmwh-tf">TF</div>
							<div class="moa-part moa-lmwh-viia">VIIa</div>
							<div class="moa-part moa-lmwh-ix">IX</div>
							<div class="moa-part moa-lmwh-ixa">IXa</div>
							<div class="moa-part moa-lmwh-xa">Xa</div>
							<div class="moa-part moa-lmwh-ii">II</div>
							<div class="moa-part moa-lmwh-iia">IIa</div>

							<div class="moa-part moa-lmwh-ii-a">II</div>
							<div class="moa-part moa-lmwh-ii-b">II</div>
							<div class="moa-part moa-lmwh-ii-c">II</div>
							<div class="moa-part moa-lmwh-ii-d">II</div>

							<div class="moa-part moa-lmwh-iia-a">IIa</div>
							<div class="moa-part moa-lmwh-iia-b">IIa</div>
							<div class="moa-part moa-lmwh-iia-c">IIa</div>
							<div class="moa-part moa-lmwh-iia-d">IIa</div>

							<div class="moa-text moa-lmwh-prothrombin">Prothrombin</div>
							<div class="moa-text moa-lmwh-thrombin">Thrombin</div>
							<div class="moa-text moa-lmwh-fibrinogen">Fibrinogen</div>
							<div class="moa-text moa-lmwh-fibrin">Fibrin</div>

							<div class="moa-line-solid moa-lmwh-x-xa">X -> Xa</div>
							<div class="moa-line-dashed moa-lmwh-tf-xa">TF -> Xa</div>
							<div class="moa-line-dashed moa-lmwh-tf-ixa">TF -> IXa</div>
							<div class="moa-line-solid moa-lmwh-ix-ixa">IX -> IXa</div>
							<div class="moa-line-dashed moa-lmwh-ixa-xa">IXa -> Xa</div>
							<div class="moa-line-dashed moa-lmwh-xa-iia">Xa -> IIa</div>
							<div class="moa-line-solid moa-lmwh-ii-iia">II -> IIa</div>
							<div class="moa-line-dashed moa-lmwh-iia-fibrin">IIa -> fibrin</div>
							<div class="moa-line-solid moa-lmwh-fibrinogen-fibrin">Fibrinogen -> fibrin</div>

							<div class="moa-lmwh-brand">LMWH</div>
							<div class="moa-lmwh-info-a">Factor Xa bound in the prothrombinase complex remains active</div>
							<div class="moa-lmwh-info-b">Indirect inhibition of free Factor Xa</div>
							<div class="moa-lmwh-info-c">Inhibition of Factor Ila</div>

							<div class="moa-lmwh-arc-a">LMWH -> Ax</div>
							<div class="moa-lmwh-arc-b">LMWH -> IIa</div>

							<div class="moa-lmwh-glow moa-lmwh-glow-a"></div>
							<div class="moa-lmwh-glow moa-lmwh-glow-b"></div>
							<div class="moa-lmwh-glow moa-lmwh-glow-c"></div>
						</div>

						<div class="moa-ani moa-fondaparinux-ani">
							<div class="moa-initiation">INITIATION</div>
							<div class="moa-propagation">PROPAGATION</div>
							<div class="moa-clotformation">CLOT FORMATION</div>

							<div class="moa-part moa-fondaparinux-x">X</div>
							<div class="moa-part moa-fondaparinux-tf">TF</div>
							<div class="moa-part moa-fondaparinux-viia">VIIa</div>
							<div class="moa-part moa-fondaparinux-ix">IX</div>
							<div class="moa-part moa-fondaparinux-ixa">IXa</div>
							<div class="moa-part moa-fondaparinux-xa">Xa</div>
							<div class="moa-part moa-fondaparinux-ii">II</div>
							<div class="moa-part moa-fondaparinux-iia">IIa</div>

							<div class="moa-part moa-fondaparinux-ii-a">II</div>
							<div class="moa-part moa-fondaparinux-ii-b">II</div>
							<div class="moa-part moa-fondaparinux-ii-c">II</div>
							<div class="moa-part moa-fondaparinux-ii-d">II</div>

							<div class="moa-part moa-fondaparinux-iia-a">IIa</div>
							<div class="moa-part moa-fondaparinux-iia-b">IIa</div>
							<div class="moa-part moa-fondaparinux-iia-c">IIa</div>
							<div class="moa-part moa-fondaparinux-iia-d">IIa</div>

							<div class="moa-text moa-fondaparinux-prothrombin">Prothrombin</div>
							<div class="moa-text moa-fondaparinux-thrombin">Thrombin</div>
							<div class="moa-text moa-fondaparinux-fibrinogen">Fibrinogen</div>
							<div class="moa-text moa-fondaparinux-fibrin">Fibrin</div>

							<div class="moa-line-solid moa-fondaparinux-x-xa">X -> Xa</div>
							<div class="moa-line-dashed moa-fondaparinux-tf-xa">TF -> Xa</div>
							<div class="moa-line-dashed moa-fondaparinux-tf-ixa">TF -> IXa</div>
							<div class="moa-line-solid moa-fondaparinux-ix-ixa">IX -> IXa</div>
							<div class="moa-line-dashed moa-fondaparinux-ixa-xa">IXa -> Xa</div>
							<div class="moa-line-dashed moa-fondaparinux-xa-iia">Xa -> IIa</div>
							<div class="moa-line-solid moa-fondaparinux-ii-iia">II -> IIa</div>
							<div class="moa-line-dashed moa-fondaparinux-iia-fibrin">IIa -> fibrin</div>
							<div class="moa-line-solid moa-fondaparinux-fibrinogen-fibrin">Fibrinogen -> fibrin</div>

							<div class="moa-fondaparinux-brand">Fondaparinux</div>
							<div class="moa-fondaparinux-info-a">Factor Xa bound in the prothrombinase complex remains active</div>
							<div class="moa-fondaparinux-info-b">Indirect inhibition of free Factor Xa via antitrombin</div>

							<div class="moa-fondaparinux-arc-a">Fondaparinux -> Ax</div>

							<div class="moa-fondaparinux-glow moa-fondaparinux-glow-a"></div>
							<div class="moa-fondaparinux-glow moa-fondaparinux-glow-b"></div>
							<div class="moa-fondaparinux-glow moa-fondaparinux-glow-c"></div>
						</div>

						<div class="moa-ani moa-dti-ani">
							<div class="moa-initiation">INITIATION</div>
							<div class="moa-propagation">PROPAGATION</div>
							<div class="moa-clotformation">CLOT FORMATION</div>

							<div class="moa-part moa-dti-x">X</div>
							<div class="moa-part moa-dti-tf">TF</div>
							<div class="moa-part moa-dti-viia">VIIa</div>
							<div class="moa-part moa-dti-ix">IX</div>
							<div class="moa-part moa-dti-ixa">IXa</div>
							<div class="moa-part moa-dti-xa">Xa</div>
							<div class="moa-part moa-dti-ii">II</div>
							<div class="moa-part moa-dti-iia">IIa</div>

							<div class="moa-part moa-dti-ii-a">II</div>
							<div class="moa-part moa-dti-ii-b">II</div>
							<div class="moa-part moa-dti-ii-c">II</div>
							<div class="moa-part moa-dti-ii-d">II</div>
							<div class="moa-part moa-dti-ii-e">II</div>
							<div class="moa-part moa-dti-ii-f">II</div>
							<div class="moa-part moa-dti-ii-g">II</div>
							<div class="moa-part moa-dti-ii-h">II</div>
							<div class="moa-part moa-dti-ii-i">II</div>
							<div class="moa-part moa-dti-ii-j">II</div>
							<div class="moa-part moa-dti-ii-k">II</div>
							<div class="moa-part moa-dti-ii-l">II</div>

							<div class="moa-part moa-dti-iia-a">IIa</div>
							<div class="moa-part moa-dti-iia-b">IIa</div>
							<div class="moa-part moa-dti-iia-c">IIa</div>
							<div class="moa-part moa-dti-iia-d">IIa</div>
							<div class="moa-part moa-dti-iia-e">IIa</div>
							<div class="moa-part moa-dti-iia-f">IIa</div>
							<div class="moa-part moa-dti-iia-g">IIa</div>
							<div class="moa-part moa-dti-iia-h">IIa</div>
							<div class="moa-part moa-dti-iia-i">IIa</div>
							<div class="moa-part moa-dti-iia-j">IIa</div>
							<div class="moa-part moa-dti-iia-k">IIa</div>
							<div class="moa-part moa-dti-iia-l">IIa</div>

							<div class="moa-text moa-dti-prothrombin">Prothrombin</div>
							<div class="moa-text moa-dti-thrombin">Thrombin</div>
							<div class="moa-text moa-dti-fibrinogen">Fibrinogen</div>
							<div class="moa-text moa-dti-fibrin">Fibrin</div>

							<div class="moa-line-solid moa-dti-x-xa">X -> Xa</div>
							<div class="moa-line-dashed moa-dti-tf-xa">TF -> Xa</div>
							<div class="moa-line-dashed moa-dti-tf-ixa">TF -> IXa</div>
							<div class="moa-line-solid moa-dti-ix-ixa">IX -> IXa</div>
							<div class="moa-line-dashed moa-dti-ixa-xa">IXa -> Xa</div>
							<div class="moa-line-dashed moa-dti-xa-iia">Xa -> IIa</div>
							<div class="moa-line-solid moa-dti-ii-iia">II -> IIa</div>
							<div class="moa-line-dashed moa-dti-iia-fibrin">IIa -> fibrin</div>
							<div class="moa-line-solid moa-dti-fibrinogen-fibrin">Fibrinogen -> fibrin</div>

							<div class="moa-dti-brand">DTI</div>
							<div class="moa-dti-info-a">Inhibition of Factor Ila</div>

							<div class="moa-dti-arc-a">DTI -> IIa</div>

							<div class="moa-dti-glow moa-dti-glow-a"></div>
							<div class="moa-dti-glow moa-dti-glow-b"></div>
							<div class="moa-dti-glow moa-dti-glow-c"></div>
						</div>

					</div>
				</article>
	      </section>	   
	   	
	   	   <section id="rocketAF_section" class="slide">
	   	      <article class="innerslide morebelow" id="rocketAF_slide1" data-monitorId="The Largest Stroke Prevention Trial of its Kind">
	   	   	<div class="rocketaf" id="rocket_af_content1">
	   	   		<h1>The Largest Stroke Prevention Trial of its Kind</h1>
	   	   		<div class="moduleClean">
	   	   			ROCKET AF is a pivotal,<br />
	   	   			<b>double-blind</b> study with over<br />
	   	   			<b>14,000</b> AF patients from<br />
	   	   			<b>1,100</b> sites across<br />
	   	   			<b>45</b> countries with a<br />
	   	   			<b>2-year</b> median follow-up<sup>11</sup>
	   	   		</div>
	   	   	</div>
	   	      </article>
	   	      <article class="innerslide morebelow moreabove" id="rocketAF_slide2" data-monitorId="ROCKET AF - Enrollment of patients without prior stroke">
	   	      <div class="rocketaf1">
	   	   	   <h1>ROCKET AF is a Rigorous,<br />Double-Blind Stroke Prevention Trial<sup>11,12</sup></h1>
	   	   	   <div class="module">
	   	   		<div class="fig6_1_right">
	   	   	    </div>
	   	   	   </div>
	   	   	   <div class="footnote"><sup>a</sup>Enrollment of patients without prior stroke, transient ischaemic attack (TIA), or systemic embolism and only 2 factors capped at 10%</div>
	   	   	  </div>
	   	   	 </article>
	   	   	 
	   	   	 <article class="innerslide morebelow moreabove" id="rocketAF_slide3" data-monitorId="ROCKET AF - Outcome measures">
	   	   	   <div class="slide6-2">
	   	   		   <h1>ROCKET AF is a Rigorous,<br />Double-Blind Stroke Prevention Trial<sup>11,12</sup></h1>
	   	   		   <div class="module">
	   	   			   <p>Primary outcome measure</p>
	   	   			   <ul>
	   	   				   <li><b>A composite of stroke and systemic embolism (SE)<sup>11</sup></b></li>
	   	   			   </ul>
	   	   	   
	   	   			   <p>Secondary outcome measures</p>
	   	   			   <ul>
	   	   				   <li>A composite of stroke, SE, and vascular death<sup>11</sup></li>
	   	   				   <li>A composite of stroke, SE, myocardial infarction (MI),<br />and vascular death<sup>11</sup></li>
	   	   			   </ul>
	   	   	   
	   	   			   <p>Principal safety outcome measure</p>
	   	   			   <ul>
	   	   				   <li>A composite of major and non-major clinically relevant<br />(NMCR) bleeding events<sup>11</sup></li>
	   	   			   </ul>
	   	   		   </div>
	   	   	 </article>
	   	   	 
	   	   	 <article id="rocketAF_slide4" class="innerslide moreabove" data-monitorId="ROCKET AF Studied Patients Commonly Seen in Daily Practice">
	   	   		 <div class="slide6-3">
	   	   			 <h1>ROCKET AF Studied Patients<br />Commonly Seen in Daily Practice</h1>
	   	   			 <p><em>In the landmark trial, Xarelto<sup>®</sup> was studied across a wide range of patients<sup>13</sup></em></p>
	   	   			 <div class="module clean">
	   	   				 <p>PATIENT DEMOGRAPHICS</p>
	   	   			 </div>
	   	   		 
	   	   			 <table>
	   	   		 		<tr>
	   	   					 <td class="noborder"><br /></td>
	   	   					 <td class="xarelto noborder tableHead">Xarelto</td>
	   	   				 </tr>
	   	   		 		<tr>
	   	   					 <td>Age</td>
	   	   					 <td class="xarelto">73 years</td>
	   	   				 </tr>
	   	   		 		<tr>
	   	   					 <td>Hypertension</td>
	   	   					 <td class="xarelto">90%</td>
	   	   				 </tr>
	   	   		 		 <tr>
	   	   					 <td>Congestive heart failure</td>
	   	   					 <td class="xarelto">63%</td>
	   	   				 </tr>
	   	   		 		  <tr>
	   	   					 <td>Prior Stroke/TIA/Systemic embolism</td>
	   	   					 <td class="xarelto">55%</td>
	   	   				 </tr>
	   	   		 		<tr>
	   	   					 <td>Diabetes</td>
	   	   					 <td class="xarelto">40%</td>
	   	   				 </tr>
	   	   		 		<tr>
	   	   					 <td>Prior MI</td>
	   	   					 <td class="xarelto">17%</td>
	   	   				 </tr>
	   	   			 </table>
	   	   			 <div class="footnote">Patient demographics were well balanced between arms, with no statistical differences.</div>
	   	   		 </div>
	   	   	 </article>
	   	   </section>
	   	   
	   		  <section id="efficacy_section" class="slide">
	   				
	   					<article class="innerslide morebelow" id="efficacy_slide1" data-monitorId="Superior Protection with Xarelto">
	   					 <div class="content-wrapper slide6">
	   					     <h1>Superior Protection with Xarelto<sup>&reg;</sup></h1>
	   					     <p>Active treatment with once-daily Xarelto vs warfarin in AF patients</p>
	   					     <div style="height: 420px;">
	   					         <p><em>Significantly reduces <em>stroke</em> and <em>systemic embolism</em><sup>12</sup></em></p>
	   					         <div class="module" style="width: 676px; height: 384px; left: 130px; background-image: url(content/images/efficacy/6.0a_graph.png);">
	   					             <div class="legend">CUMULATIVE<br/>EVENT RATE (%)</div>
	   					             <div class="effGraphArrow"><br /></div>
	   					         </div>
	   					         <div class="ref1">
	   					             <p>Pre-specified, on treatment analysis in the safety population.</p>
	   					         </div>
	   					     </div>
	   					 </div>
	   					</article>
	   					
	   						<article class="innerslide morebelow moreabove" id="efficacy_slide2" data-monitorId="Improved CV Protection with Xarelto">
	   							<div class="content-wrapper slide61 itemStates">
	   							    <h1><a href="#">Improved CV Protection with Xarelto<sup>&reg;</sup>.<br/>More Patient Benefits</a></h1>
	   							    <p>Active treatment with once-daily Xarelto vs warfarin in AF patients</p>
	   							    
	   							   <div class="hideElem" style="height: 420px;">
	   							    <p><em>Significantly reduces <em>overall CV outcomes</em>.<br/><span>(composite of stroke, systemic embolism, MI, and vascular death)<sup>12</sup></span></em></p>
	   							        <div class="module" style="width: 559px; height: 309px; left: 210px; background-image: url(content/images/efficacy/graph.png)">
	   							    		<div class="legend">EVENT RATE PER<br/>100 PT-YRS</div>		
	   							    		<ul class="pillars">
	   							    			<li class="brown">
	   							    				<div class="pillar">
	   							    					<img src="content/images/efficacy/pillar-brown.png" alt="">
	   							    				</div>
	   							    			</li>
	   							    			<li class="magenta">
	   							    				<div class="pillar">
	   							    					<img src="content/images/efficacy/pillar-magenta.png" alt="">
	   							    				</div>
	   							    			</li>
	   							    		</ul>
	   							    		<img src="content/images/efficacy/drop-arrow.png" alt="" class="dropArrow"/>
	   							    	</div>                     
	   							    </div>                      
	   							    
	   							    <div class="hideElem" style="height: 420px;">
	   							    	<p><em>Patients on Xarelto experienced numerically<br />fewer CV events vs warfarin<sup>12</sup></em></p>				           
	   							        <dl class="diamonds">
	   										<dt>MI</dt>
	   										<dd><p><em>Xarelto (0.91) vs<br /> warfarin (1.12)<sup>12</sup></em></p></dd>
	   										<dt>VASCULAR<br />DEATH</dt>
	   										<dd><p><em>Xarelto (1.53) vs<br /> warfarin (1.71)<sup>12</sup></em></p></dd>
	   									</dl>
	   							    </div>
	   						        
	   								<div class="ref2">
	   						            <p>All values are expressed as event rate per 100 patient-years<br/> and are
	   						             from the pre-specified, on-treatment analysis in the <br/>safety population</p>
	   						        </div> 	   						    
	   								<ul class="dLinks">
	   							          <li class="dLink1">Overall CV <br /> Outcomes</li>
	   							          <li class="dLink2">MI and <br />Vascular Death</li>
	   							      </ul>
	   							</div>						
	   					</article>
	   						   				
	   				<article class="innerslide moreabove" id="efficacy_slide3" data-monitorId="Trust a Benefit-Risk Profile with Proven Protection">
	   					 <div class="efficacy_background">
	   		  			 <h1><a href="#">Trust a Benefit-Risk Profile <br/>with Proven Protection</a></h1>
	   		  			 <p>AF patients on Xarelto benefit from better overall protection: <br/>
	   		  			 superior efficacy and demonstrated safety<em>Multiple points of protection with Xarelto<sup>&reg;</sup></em>
	   		  			 </p>
	   		  			 <div class="efficacy0"></div>
	   		  			 <div class="ref zoom" id="efficacy_zoom">
	   		  			 	<p><strong><sup>a</sup>Major + Non-major clinically relevant bleeding:</strong> event rate per 100 patient-years (14.91 vs 14.52).<br />
	   		  			 		 <strong><sup>b</sup>Major bleeding:</strong> bleeding associated with a ≥2 g/dL fall in haemoglobin or requirement for transfusion of ≥2 units of packed
	   		  			 	red blood cells or whole blood (clinically overt bleeding); the involvement of a critical site; or a fatal outcome. Event rate per 100
	   		  			 	patient-years (3.60 vs 3.45).<br />
	   		  			 	<strong><sup>c</sup>Non-major clinically relevant bleeding:</strong> overt bleeding not meeting the criteria for major bleeding but associated with
	   		  			 	medical intervention; unscheduled contact with a physician; temporary study drug cessation; pain; or impairment of daily activities.
	   		  			 	Event rate per 100 patient-years (11.80 vs 11.37).</p>	   		  			 </div>					
	   					  </div>
	   			    </article>
	   			</section>		  
	   		  	
	   			<section id="safety_section" class="slide">
	   			<article class="innerslide morebelow" id="safety_slide1" data-monitorId="Xarelto Significantly Reduces ICH and Fatal Bleeding Events">
	   			<div class="slide7">
	   			<h1>Xarelto<sup>&reg;</sup> Significantly Reduces<br/>ICH and Fatal Bleeding Events</h1>
	   			<p>Active treatment with once-daily Xarelto vs warfarin in AF patients shows similar overall<br/>bleeding in the composite of major and non-major clinically relevant bleeding events<em>Reduce the risk of the most critical bleeds in your AF patients<sup>12</sup></em></p>
	   
	   			<dl class="diamonds">
	   				<dt>50%<span>RRR</span></dt>
	   				<dd><p><em>Reduced fatal bleeding events </em>Xarelto (0.24) vs warfarin (0.48), <i>P</i>=0.003<sup>12</sup></p></dd>
	   				<dt>33%<span>RRR</span></dt>
	   				<dd><p><em>Fewer ICH events </em>Xarelto (0.49) vs warfarin (0.74), <i>P</i>=0.019<sup>12</sup></p></dd>
	   				<dt>31%<span>RRR</span></dt>
	   				<dd><p><em>Fewer critical organ bleeding events </em>Xarelto (0.82) vs warfarin (1.18), <i>P</i>=0.007<sup>12</sup></p></dd>
	   			</dl>
	   			<div class="ref zoom" id="safety_zoom">
	   				<p>All values are expressed as event rate per 100 patient-years. Patients on Xarelto had significant<br /> increases in the following major bleeding events:.a ≥2 g/dL fall in haemoglobin (2.8% vs. 2.3%, P=0.019) and transfusions (1.7% vs. 1.3%, P=0.044).</p>
	   				<p><strong>Major bleeding</strong>: bleeding associated with a ≥2 g/dL fall in haemoglobin or requirement for transfusion of ≥2 units of packed red blood cells or .whole blood (clinically overt bleeding); the involvement of a critical site; or a fatal outcome.</p>
	   				<p><strong>Non-major clinically relevant bleeding</strong>: overt bleeding not meeting the criteria for major bleeding but associated with medical intervention; unscheduled contact with a physician; temporary study drug cessation; pain; or impairment of daily activities. ICH=intracranial haemmorhagic.</p>
	   			</div>
	   			</div>
	   			</article>
	   			
	   			<article class="innerslide moreabove" id="safety_slide2" data-monitorId="Trust a Benefit-Risk Profile with Proven Protection">
	   			<div class="safety2">
	   			<h1><a href="#">Trust a Benefit-Risk Profile <br/>with Proven Protection</a></h1>
	   			<p>AF patients on Xarelto benefit from better overall protection: <br/>
	   			superior efficacy and demonstrated safety<em>Multiple points of protection with Xarelto<sup>&reg;</sup></em>
	   			</p>
	   			<div class="safety0"></div>
	   			<div class="ref bottom" id="safety_zoom2">
	   				<p><strong><sup>a</sup>Major + Non-major clinically relevant bleeding:</strong> event rate per 100 patient-years (14.91 vs 14.52).<br />
	   					 <strong><sup>b</sup>Major bleeding:</strong> bleeding associated with a ≥2 g/dL fall in haemoglobin or requirement for transfusion of ≥2 units of packed
	   				red blood cells or whole blood (clinically overt bleeding); the involvement of a critical site; or a fatal outcome. Event rate per 100
	   				patient-years (3.60 vs 3.45).<br />
	   				<strong><sup>c</sup>Non-major clinically relevant bleeding:</strong> overt bleeding not meeting the criteria for major bleeding but associated with
	   				medical intervention; unscheduled contact with a physician; temporary study drug cessation; pain; or impairment of daily activities.
	   				Event rate per 100 patient-years (11.80 vs 11.37).</p>
	   			</div>
	   			</div>
	   		</article>
	   	   </section> 
	   			
	   			
	   		<section id="administration_section" class="slide">
	   			<article id="administration_slide" data-monitorId="More Protection with Less Worry">
	   			 	<div class="slide8" id="slide8">
 						<h1><a href="#">One-Tablet, Once-Daily Xarelto<sup>&reg;</sup> -<br/>More Protection with Less Worry<sup>7</sup></a></h1>
 						<p><em>Superior protection in one simple fixed dose<sup>7</sup></em></p>
  						<dl class="diamonds wide">
 							<dt>20 mg</dt>
 							<dd><img src="content/images/administration/pill.png" alt=""/><p>One 20-mg tablet, once daily for your AF patients<sup>7</sup></p></dd>
 						</dl>
 
 						<p class="ref">One 15-mg tablet, once daily for patients with moderate renal impairment (creatinine clearance of 30-49 mL/min)<sup>7</sup></p>
 
 						<ul class="foldouts clickAndAnimate">
 							<li>
 								<a href="#" class="toggler">
 									<h3>Simple to initiate</h3>
 									<div class="content">
 										<ul>
 											<li>For your new AF patients, Xarelto provides protection from day one<sup>15</sup></li>
 											<li>For AF patients taking VKA, stop VKA treatment. Once INR ≤ 3.0, start Xarelto<sup>7</sup></li>
 										</ul>
 									</div>
 								</a>
 							</li>
 
 							<li>
 								<a href="#" class="toggler">
 									<h3>Simple to manage</h3>
 									<div class="content">
 										<ul>
 											<li>No coagulation monitoring, low risk of drug-drug interactions, no dietary restrictions<sup>8</sup></li>
 											<li>Good tolerability<sup>12</sup></li>
 										</ul>
 									</div>
 								</a>
 							</li>
 						</ul>
 
 						<div class="ref bottom">
 							<p>VKA= vitamin K antagonist.<br/>Xarelto is not recommended for patients with prosthetic heart valves.<br />
 							INR values should not be used. They are not a dependable measure of the anticoagulant activity of Xarelto.</p>
 						</div>
 					</div>
 				</article>	   			
	   			</section> 
	   		   
	   			<section id="summary_section" class="slide">
	   			<article id="summary_slide" data-monitorId="Once-Daily Xarelto Simply Protects More of Your AF Patients">
	   		   		<div class="slide9" id="slide9">
	   				<h1><a href="#">Once-Daily Xarelto<sup>&reg;</sup> Simply Protects<br/>More of Your AF Patients</a></h1>
	   				<p><em>Active treatment with once-daily Xarelto vs warfarin:</em></p>
	   	
	   				<ul class="diamonds clickAndAnimate">
	   					<li class="activ">
	   						<a href="#" class="toggler">
	   							<h3>Simply</h3>
	   							<div class="content">
	   								<p><em>PROVIDING SUPERIOR PROTECTION</em><br/>against stroke and systemic embolism<sup>12</sup></p>
	   							</div>
	   						</a>
	   					</li>
	   					<li>
	   						<a href="#" class="toggler">
	   							<h3>Protecting</h3>
	   							<div class="content">
	   								<p><em>AGAINST MOST CRITICAL BLEEDS</em><br/>including ICH and fatal bleeding events<sup>12</sup></p>
	   							</div>
	   						</a>
	   					</li>
	   					<li>
	   						<a href="#" class="toggler">
	   							<h3>More</h3>
	   							<div class="content">
	   								<p><em>CARDIOVASCULAR PROTECTION</em> with reduced overall CV outcomes (composite of stroke, systemic embolism, MI, and vascular death)<sup>12</sup></p>
	   							</div>
	   						</a>
	   					</li>
	   					<li>
	   						<a href="#" class="toggler">
	   							<h3>Patients</h3>
	   							<div class="content">
	   								<p><em>BENEFIT FROM SIMPLIFIED TREATMENT</em> with <br>one-tablet, once-daily dosing with no monitoring<sup>7,9</sup></p>
	   							</div>
	   						</a>
	   					</li>
	   				</ul>
	   			   </div>
	   		 </article>
	   		</section>	    
	  </div>
   </div>
   <div id="cover" class="cover">
         <section id="home_section" class="slide">  
         	 <article id="home_cover" data-monitorId="Home">
         	   <div class="slide_cover" id="home">
         	   <div class="frontLegCover"></div>
         	   <div class="frontSpafContainer">
         	   <div class="frontBrain"></div>
         	   <p class="frontTitle">Stroke Prevention<br />for Patients with Atrial Fibrillation</p>
         	   <div class="frontVein"><br /></div>
         	   </div>
         	   </div>
         	</article>
          </section>
   </div>

   
   <div id="thumbnav" class="thumbnav">
   
   <ul section-id="references_section">
   	<li><img src="content/images/thumbnails/T_1.0.png" alt=""></li>
   </ul>
   
   <ul section-id="home_section none">
   	<li></li>
   </ul>
   
   <ul section-id="stroke_in_af_section">
   	<li><img src="content/images/thumbnails/T_2.0.png" alt=""></li>
   </ul>
   
   <ul section-id="current_treatment_section">
   	<li><img src="content/images/thumbnails/T_3.png" alt=""></li>
   </ul>
   
   <ul section-id="xarelto_section">
   	<li><img src="content/images/thumbnails/T_4.0.png" alt=""></li>
   	<li><img src="content/images/thumbnails/T_4.1.png" alt=""></li>
   </ul>
   
   <ul section-id="rocketAF_section">
   	<li><img src="content/images/thumbnails/T_6.0.png" alt=""></li>
   	<li><img src="content/images/thumbnails/T_6.1.png" alt=""></li>
   	<li><img src="content/images/thumbnails/T_6.2.png" alt=""></li>
   	<li><img src="content/images/thumbnails/T_6.3.png" alt=""></li>
   </ul>
   
   	<ul section-id="efficacy_section">
   		<li><img src="content/images/thumbnails/T_5.0.png" alt=""></li>
   		<li><img src="content/images/thumbnails/T_5.1.png" alt=""></li>
   		<li><img src="content/images/thumbnails/T_7.1.png" alt=""></li>
   	</ul>
  
   	<ul section-id="safety_section">
   		<li><img src="content/images/thumbnails/T_7.0.png" alt=""></li>
   		<li><img src="content/images/thumbnails/T_7.1.png" alt=""></li>
   	</ul>
   	
   	<ul section-id="administration_section">
   		<li><img src="content/images/thumbnails/T_8.0.png" alt=""></li>
   	</ul>
   	
   	<ul section-id="summary_section">
   		<li><img src="content/images/thumbnails/T_9.0.png" alt=""></li>
   	</ul>
   	<div id="brain" class="branding"></div>
   </div>
   
   <div id="footer" class="footer"></div>  
   <div id="references_button" class="referencesbutton"></div>
   </div>
   
   <div id="zoomWindow" class="zoomWindow">
   	  <div id="popupupContainer" class="popupContainer">
   	  <div id="popup" class="popup">
   	  <div class="text">
   	 <p>All values are expressed as event rate per 100 patient-years. Patients on Xarelto had significant<br /> increases in the following major bleeding events:.a ≥2 g/dL fall in haemoglobin (2.8% vs. 2.3%, P=0.019) and transfusions (1.7% vs. 1.3%, P=0.044).</p>
   	 <p><strong>Major bleeding</strong>: bleeding associated with a ≥2 g/dL fall in haemoglobin or requirement for transfusion of ≥2 units of packed red blood cells or .whole blood (clinically overt bleeding); the involvement of a critical site; or a fatal outcome.</p>
   	 <p><strong>Non-major clinically relevant bleeding</strong>: overt bleeding not meeting the criteria for major bleeding but associated with medical intervention; unscheduled contact with a physician; temporary study drug cessation; pain; or impairment of daily activities. ICH=intracranial haemmorhagic.</p>
   	  </div>
   	  </div>
   	  </div>
   </div>
   
   <div id="zoomWindow2" class="zoomWindow">
       <div id="popupupContainer" class="popupContainer">
       <div id="popup" class="popup">
       <div class="text">
   	   <p><strong><sup>a</sup>Major + Non-major clinically relevant bleeding:</strong> event rate per 100 patient-years (14.91 vs 14.52).<br />
   	  	 <strong><sup>b</sup>Major bleeding:</strong> bleeding associated with a ≥2 g/dL fall in haemoglobin or requirement for transfusion of ≥2 units of packed
   	  red blood cells or whole blood (clinically overt bleeding); the involvement of a critical site; or a fatal outcome. Event rate per 100
   	  patient-years (3.60 vs 3.45).<br />
   	  <strong><sup>c</sup>Non-major clinically relevant bleeding:</strong> overt bleeding not meeting the criteria for major bleeding but associated with
   	  medical intervention; unscheduled contact with a physician; temporary study drug cessation; pain; or impairment of daily activities.
   	  Event rate per 100 patient-years (11.80 vs 11.37).</p>
   	  </div>
   	 </div>
   	 </div>
   </div>
   
   <div id="popupWindow" class="popupWindow">
   	  <div id="popupupContainer" class="popupContainer">
   	  <div id="popup" class="popup">
   	        <h1>References</h1>
   			<ul slide-id="stroke_in_af" class="references">
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref01_Di_Carlo-Humanandeconomicburdenofstroke.pdf');"><span>1.</span>
   			 	    Di Carlo A. Human and economic burden of stroke. Age Ageing. 2009;38(1):4-5. </a>
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref02_Kannel-PrevalenceincidencePrognosis.pdf');"><span>2.</span>
   			 	  Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation:
   			 	  population-based estimates. Am J Cardiol. 1998;82(8A):2N-9N. </a>
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref03_Marinietal-ContributionofAtrialFibrillationtoIncidenceandOutcomeofIschemicStroke.pdf');"><span>3.</span>
   			 	  Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke.
   			 	   2005;36(6):1115-1119.</a>
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref04_Gladstone-PotentiallyPreventableStrokesinHigh-RiskPatientsWithAtrialFibrillation.pdf');"><span>4.</span>
   			 	   Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235-240. </a>
   			 	</li>
   			 </ul>
   			
   		 	<ul slide-id="current_treatment" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref04_Gladstone-PotentiallyPreventableStrokesinHigh-RiskPatientsWithAtrialFibrillation.pdf');"><span>4.</span>
   		 		   Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40(1):235-240. </a>
   		 		</li>
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref05_Warfarin_SPC.pdf');"><span>5.</span>
   		 		    Warfarin [summary of product
   		 		    characteristics]. Frimley, Camberley, Surrey, United Kingdom: Sandoz Ltd; October 2010. </a>
   		 		</li>
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref06_Waldo-HospitalizedPatientsWithAtrialFibrillationandaHighRiskofStroke.pdf');"><span>6.</span>
   		 		  Waldo AL, Becker RC, Tapson VF, et al; NABOR Steering Committee. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol. 2005;46(9):1729-1736. 
   		 		 </a>
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="xarelto_slide1" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
   		 		   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="xarelto_slide2" class="references">
   				<li>
   				<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
   				   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
   				</li>
   			</ul>
   		 	
   		 	<ul slide-id="efficacy_slide1" class="references">
   		 		<li class="none">
   		 		<span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="efficacy_slide2" class="references">
   		 		<li class="none">
   		 		<span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="rocketAF_slide1" class="references">
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref11_DesignRocketAF.pdf');"><span>11.</span>
   			 	  The Executive Steering Committee, on
   			 	  behalf of the ROCKET AF Study Investigators. Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of
   			 	  the ROCKET AF study. Am Heart J. 2010;159(3):340-347. </a>
   			 	</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="rocketAF_slide2" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref11_DesignRocketAF.pdf');"><span>11.</span>
   		 		  The Executive Steering Committee, on
   		 		  behalf of the ROCKET AF Study Investigators. Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of
   		 		  the ROCKET AF study. Am Heart J. 2010;159(3):340-347. </a>
   		 		</li>
   		 		<li class="none">
   		 		 <span>12.</span>
   		 		 Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="rocketAF_slide3" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref11_DesignRocketAF.pdf');"><span>11.</span>
   		 		  The Executive Steering Committee, on
   		 		  behalf of the ROCKET AF Study Investigators. Rivaroxaban—once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of
   		 		  the ROCKET AF study. Am Heart J. 2010;159(3):340-347. </a>
   		 		</li>
   		 		<li class="none">
   		 		 <span>12.</span>
   		 		 Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="rocketAF_slide4" class="references">
   		 		<li>
   		 		<a href="javascript:openPDF('docs/Ref13_Hacke-BaselinecharacteristicsofROCKETAFstudy.pdf');"><span>13.</span>
   		 		  Hacke W, Patel MR, Becker RC, et al. Baseline characteristics of the ROCKET AF study: comparison with recent
   		 		  atrial fibrillation studies. Abstract OAID 5 presented at the 19th European Stroke Conference (ESC); May 25-28, 2010: Barcelona, Spain 2010. 
   		 		  </a>
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="safety_slide1" class="references">
   		 		<li class="none">
   		 		 <span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="safety_slide2" class="references">
   		 		<li class="none">
   		 		 <span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="administration_slide" class="references">
   			 	<li>
   			 	<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
   			 	   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref08_Perzborn-Thediscoveryanddevelopmentofrivaroxaban.pdf');"><span>8.</span>
   			 	  Perzborn E, Roehrig S, Straub A, et al. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2010;10(1):61-75.</a>
   			 	</li>
   		 		<li class="none">
   		 		<span>12.</span>
   		 		Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 		<li>
   		 		 <a href="javascript:openPDF('docs/Ref15_Kubitza-Safetypharmacodynamics.pdf');"><span>15.</span>
   		 		  Kubitza D, Becka M, Wensing G,
   		 		  et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61(12):873-880.</a>
   		 		</li>
   		 	</ul>
   		 	
   		 	<ul slide-id="summary_slide" class="references">
   			 	<li>
   			 	<a href="javascript:openPDF('docs/7.pdf');"><span>7.</span>
   			 	   Xarelto [summary of product characteristics], draft. Leverkusen, Germany: Bayer HealthCare AG; December 2010.</a> 
   			 	</li>
   			 	<li>
   			 	<a href="javascript:openPDF('docs/Ref09_Perzborn-Invitroandinvivostudiesofthenovelantithromboticagent.pdf');"><span>9.</span>
   			 	   Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic
   			 	   agent BAY 59-7939—an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3(3):514-521. </a>
   			 	</li>
   		 		<li class="none">
   		 		<span>12.</span>
   		 		  Data on file. Bayer HealthCare AG, Berlin, Germany.
   		 		</li>
   		 	</ul>
   	  </div>
   	     <div class="closebutton" id="popupclosebutton"></div>
   </div>
   

    
  </div>
</body>
</html>   
